Want to join the conversation?
$ALXN 2Q15 PR: Net product sales of Soliris (eculizumab) grew to $636MM, a 24% increase compared to $512.5MM in 2Q15, despite currency headwinds. Positive CHMP opinions were received for Strensiq (asfotase alfa) for Hypophosphatasia (HPP) and Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D) in the European Union.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.